神经肽研究的一些进展

自从70年代初以下丘脑各种释放激素结构阐明为标志的神经肽研究兴起以来,20年过去了。人们可以看出,这个领域已从以发现新神经肽为主走向深入研究作用原理的阶段。本文着重从释放、受体结构、受体的非肽类配体以及作用方式四个方面介绍神经肽研究的进展。 1 神经肽释放需要较高的刺激频率利用外周神经系统的实验标本,发现电刺激频率必须高才能引起其所含的神经肽释放,     

神经肽拮抗剂

由于肽的分离纯化、结构分析、化学合成、放射免疫、组织化学定位以及重组DNA等技术的应用,已发现的神经肽的数目与日俱增;但其中多数神经肽的生理功能尚不清楚,原因之一是缺乏特异性的拮抗剂。在神经系统中,神经肽可能起神经递质或神经调节物的作用;在神经内分泌、旁分泌及内分泌系统,又可能起激素的作用。神经肽拮抗剂能在受体水平阻断神经肽的作用,因而可用来推测神经肽在生理及病理状态下的功能;它们又可用于神经肽受体性质的研究以及受体亚型的分型。它们可能发展成为新型的诊断药或治疗药。     

PBAN/pyrokinin神经肽类及其基因的研究进展

昆虫在其生长发育过程中,如胚胎发育、蜕皮变态、滞育、迁飞、代谢、生殖等都离不开神经肽的调控。信息素合成激活肽(pheromone biosynthesis activating neuropeptide,PBAN)和Pyrokinin神经肽是C端具有五肽FXPRL(X=S,V,T,G等)(苯丙-X-脯-精-亮氨酸)序列的一类神经肽,在昆虫的生长发育中起重要的生理功能,如性信息素的合成、控制表皮色素、促进胚胎滞育和刺激内脏肌肉收缩等重要的生理功能。因此近几年对PBAN/pyrokinin神经肽的鉴定、加工、作用和降解方式的研究成为研究的热点,为研制高效、低毒、专一性强、无公害的杀虫剂提供了思路。介绍了PBAN/pyrokinin神经肽类及其基因的研究进展,并对PBAN/pyrokinin神经肽在害虫防治中的应用进行了展望。     

神经肽Y(NPY)的生理功能研究进展

神经肽Y(NPY)是机体内的一种重要且保守的神经递质,一般以前体形式存在,释放的有活性的NPY主要通过与其受体结合发挥作用。NPY受体包含了亚型Y1、Y2、Y3、Y4、Y5、Y6、Y7、Y8。Y1和Y2是NPY发挥收缩血管作用的关键受体;Y1、Y2和Y5是NPY调节动物摄食行为的关键受体;Y1、Y2和Y4是NPY调控动物焦虑、沮丧行为的必要受体。着重对NPY与其各种受体结合后如何行使动物的相关生理功能的情况进行了阐述。     

神经肽Y参与痛觉调制的研究进展

神经肽Y（NPY）是中枢神经系统内含量最多的神经肽之一,它参与机体多种生理活动。近年来,对不同痛模型中NPY作用的研究表明,NPY可能通过激活脊髓和脊髓上水平的Y1受体或拮抗背根节的Y2受体发挥镇痛作用,此类研究将为NPY及其受体激动剂在镇痛中的应用提供重要的理论基础。本文就NPY及其Y1、Y2受体在痛觉调制中的作用作一简要综述。     

家蚕神经肽及其受体的功能和信号转导机制研究进展

神经肽是一类由神经分泌细胞分泌、用于调节生物胞间信号传递的信号分子,其信号分子的膜定位、相应胞内信使的激活以及一系列级联反应的引发,是由存在于细胞表面的特异性受体分子来完成的。神经肽及其受体能够调控昆虫的几乎所有生命活动,在昆虫生长发育中起着关键作用。家蚕Bombyx mori作为鳞翅目昆虫的模式物种,是昆虫生长发育与生理学研究的重要模型。特别是家蚕基因组测序完成后,越来越多的家蚕神经肽及其受体被鉴定,并发现其在家蚕的生长发育、取食消化、蜕皮、滞育、繁殖、吐丝结茧等各种生理活动中都发挥了重要的调节作用。本文综述了家蚕重要神经肽的种类及其对家蚕取食消化、蜕皮变态、生殖发育等的调控作用,探讨了神经肽通过结合特异性受体而激活细胞内ERK、TOR等下游信号通路的分子作用机制,以期为昆虫神经肽及其受体研究提供借鉴和参考,并以此推进家蚕功能基因的研究,促进蚕丝产业的发展。     

神经肽的免疫调节作用

机体自我免疫耐受的降低或者破坏会导致免疫系统的失衡,并加重炎症反应过程,从而引发多种自身免疫性疾病.所以诱导免疫耐受并终止炎症反应对恢复机体健康具有十分重要的意义.最近研究发现机体在炎症反应过程中会释放一类神经肽,如VIP,urocortin,ghrelin等.这些神经肽可下调固有免疫应答,抑制抗原特异性Th1细胞分化,诱导调节性T细胞的产生,维持免疫耐受,并终止炎症反应.神经肽的这种抑炎作用主要是通过激活cAMP-PKA通路以及调节与免疫炎症因子表达相关的信号通路来实现的.神经肽有可能成为治疗炎症性疾病的一类新药物.     

神经肽Y_2受体对神经病理痛调制的研究进展

神经肽Y2受体（neuropeptideY2 receptor,NPY2R）是一种在很多生理及病理情况下广泛分布、表达于哺乳动物的G蛋白耦联受体。Y2受体在众多生理作用及疾病中发挥重要影响,通过神经肽Y在脊髓及脊髓以上水平的作用,Y2受体对神经病理痛的形成有密切联系。本文拟从Y2受体分子生物学基础、相关的作用机制及涉及神经病理痛实验研究方面,就Y2受体对痛觉调制中的作用作简单综述。     

神经肽在中枢和外周对大鼠胃粘膜血流量的调节作用

目的 :系统研究降钙素基因相关肽 (CGRP)、胃泌素 17(G17)、蛙皮素 (Bom)、甲基脑啡肽 (Met enk)、神经肽Y(NPY)和生长抑素 (SS)在中枢及外周对胃粘膜血流量 (GMBF)的影响及内源性NO在神经肽所致GMBF增加效应中的作用。方法 :采用氢气清除法测定GMBF以及近胃动脉灌注和侧脑室微量注射神经肽技术。结果 :①近胃动脉灌注CGRP和G17(5、5 0和 10 0pmol·min-1)均明显地、剂量依赖性地增加GMBF ,其中CGRP作用最强。事先静脉注射NO的生物合成阻滞剂L NAME ,可分别完全和部分阻断CGRP和G17的这一效应。②近胃动脉灌注5 0和 10 0pmol·min-1剂量的Bom和Met enk时 ,GMBF显著增加 ;L NAME可完全抑制Bom增加GMBF的效应 ,但仅部分阻断Met enk引起的效应。③近胃动脉灌注NPY(5、5 0和 10 0 pmol·min-1)可使GMBF明显降低 ,此作用具量效关系 ;SS(5 0和 10 0 pmol·min-1)亦可使GMBF明显降低。④侧脑室注射 10 μgCGRP和G17可使GMBF显著增加 ;L NAME可完全阻断CGRP的此效应 ,但仅部分阻断G17所致的GMBF增加效应。⑤侧脑室注射NPY(10 μg)可显著降低GMBF。 结论 :神经肽在大鼠GMBF的调节中具有十分重要的作用。在神经肽所致GMBF增加效应中 ,NO作为第二介质而发挥作用     

Molecular evolution of the neuropeptide S receptor

The neuropeptide S receptor (NPSR) is a recently deorphanized member of the G protein-coupled receptor (GPCR) superfamily and is activated by the neuropeptide S (NPS). NPSR and NPS are widely expressed in central nervous system and are known to have crucial roles in asthma pathogenesis, locomotor activity, wakefulness, anxiety and food intake. The NPS-NPSR system was previously thought to have first evolved in the tetrapods. Here we examine the origin and the molecular evolution of the NPSR using in-silico comparative analyses and document the molecular basis of divergence of the NPSR from its closest vertebrate paralogs. In this study, NPSR-like sequences have been identified in a hemichordate and a cephalochordate, suggesting an earlier emergence of a NPSR-like sequence in the metazoan lineage. Phylogenetic analyses revealed that the NPSR is most closely related to the invertebrate cardioacceleratory peptide receptor (CCAPR) and the group of vasopressin-like receptors. Gene structure features were congruent with the phylogenetic clustering and supported the orthology of NPSR to the invertebrate NPSR-like and CCAPR. A site-specific analysis between the vertebrate NPSR and the well studied paralogous vasopressin-like receptor subtypes revealed several putative amino acid sites that may account for the observed functional divergence between them. The data can facilitate experimental studies aiming at deciphering the common features as well as those related to ligand binding and signal transduction processes specific to the NPSR.     

Anxiolytic-like effect of neuropeptide S in the rat defensive burying

Neuropeptide S (NPS) has been recently identified as the endogenous ligand of a previously orphan G-protein-coupled receptor now named NPSR. Both NPS and its receptor are expressed in the brain, where they modulate different functions. In particular, it has been demonstrated that intracerebroventricular (i.c.v.) injection of NPS in rodents increases wakefulness and promotes anxiolytic-like effects. In the present study we used the defensive burying (DB) test in rats to further investigate the action of human NPS (0.1–10 nmol, i.c.v.) on anxiety-related behaviors. Diazepam (1.5 mg/kg, i.p.) and caffeine (20 mg/kg, i.p.) were used in parallel experiments as standard anxiolytic and anxiogenic drugs, respectively. None of the tested drugs produced statistical differences in the latency to contact the probe, burying behavior latency, number of shocks received or immobility/freezing duration. Caffeine increased cumulative burying behavior and the buried bedding height in a statistically significant manner thus promoting anxiogenic like effects. Opposite results were obtained with diazepam that significantly reduced these behavioral parameters. The anxiolytic-like action of diazepam was mimicked by NPS that reduced cumulative burying behavior in a dose dependent manner. Collectively, robust anxiolytic-like effects were recorded in response to NPS in the DB test. These results are of particular interest since the outcome of this assay is marginally influenced by drug effects on locomotor activity. In conclusion, we provide further evidence that NPS evokes genuine anxiolytic-like effects in the rat; therefore NPSR selective agonists are worthy of development as innovative drugs for the treatment of anxiety disorders.     

Neuropeptide S: a neuropeptide promoting arousal and anxiolytic-like effects

Arousal and anxiety are behavioral responses that involve complex neurocircuitries and multiple neurochemical components. Here, we report that a neuropeptide, neuropeptide S (NPS), potently modulates wakefulness and could also regulate anxiety. NPS acts by activating its cognate receptor (NPSR) and inducing mobilization of intracellular Ca2+. The NPSR mRNA is widely distributed in the brain, including the amygdala and the midline thalamic nuclei. Central administration of NPS increases locomotor activity in mice and decreases paradoxical (REM) sleep and slow wave sleep in rats. NPS was further shown to produce anxiolytic-like effects in mice exposed to four different stressful paradigms. Interestingly, NPS is expressed in a previously undefined cluster of cells located between the locus coeruleus (LC) and Barrington's nucleus. These results indicate that NPS could be a new modulator of arousal and anxiety. They also show that the LC region encompasses distinct nuclei expressing different arousal-promoting neurotransmitters.     

Structure-function relationships in the neuropeptide S receptor: molecular consequences of the asthma-associated mutation N107I

Neuropeptide S (NPS) and its receptor (NPSR) are thought to have a role in asthma pathogenesis; a number of single nucleotide polymorphisms within NPSR have been shown to be associated with an increased prevalance of asthma. One such single nucleotide polymorphism leads to the missense mutation N107I, which results in an increase in the potency of NPS for NPSR. To gain insight into structure-function relationships within NPS and NPSR, we first carried out a limited structural characterization of NPS and subjected the peptide to extensive mutagenesis studies. Our results show that the NH(2)-terminal third of NPS, in particular residues Phe-2, Arg-3, Asn-4, and Val-6, are necessary and sufficient for activation of NPSR. Furthermore, part of a nascent helix within the peptide, spanning residues 5 through 13, acts as a regulatory region that inhibits receptor activation. Notably, this inhibition is absent in the asthma-linked N107I variant of NPSR, suggesting that residue 107 interacts with the aforementioned regulatory region of NPS. Whereas this interaction may be at the root of the increase in potency associated with the N107I variant, we show here that the mutation also causes an increase in cell-surface expression of the mutant receptor, leading to a concomitant increase in the maximal efficacy (E(max)) of NPS. Our results identify the key residues of NPS involved in NPSR activation and suggest a molecular basis for the functional effects of the N107I mutation and for its putative pathophysiological link with asthma.     

Effects of neuropeptide S on the proliferation of splenic lymphocytes, phagocytosis, and proinflammatory cytokine production of pulmonary alveolar macrophages in the pig

Neuropeptide S (NPS), a newly identified neuropeptide, is involved in many physiological and pathological activities through the NPS receptor (NPSR). Recently, the NPS and NPSR have been detected in peripheral systems of pigs including immune tissues, suggesting that NPS may play an important role in the regulation of immune function. The aim of this study was to demonstrate the presence and function of NPS and NPSR in splenic lymphocytes (SPLs) and pulmonary alveolar macrophages (PAMs) of pigs. By RT-PCR, the expression of NPS and NPSR mRNA was detected in the SPLs and PAMs. NPS immunoreactivity was observed in the membrane and cytoplasm of both SPLs and PAMs. We found that NPS could stimulate the proliferation of SPLs, when NPS was added at concentrations of 0.01, 0.1, 1, 10, 100 and 1000 nM alone or in combination with PHA/LPS in vitro. In macrophages from bronchoalveolar lavage (BAL) fluid of pigs, various doses of NPS (0.01, 0.1, 1, 10, 100 and 1000 nM) up-regulated the phagocytosis of PAMs in comparison to controls. In PAMs, NPS could induce the production of the pro-inflammatory cytokines IL-1β, IL-6 and TNF-α. Taken together, all data suggest that NPS is capable of inducing phagocytosis of non-opsonized E. coli. NPS might act as potent neuroimmunomodulatory factors and affects the maintenance of immune homeostasis.     

Neuropeptide S Facilitates Mice Olfactory Function through Activation of Cognate Receptor-Expressing Neurons in the Olfactory Cortex

Neuropeptide S (NPS) is a newly identified neuromodulator located in the brainstem and regulates various biological functions by selectively activating the NPS receptors (NPSR). High level expression of NPSR mRNA in the olfactory cortex suggests that NPS-NPSR system might be involved in the regulation of olfactory function. The present study was undertaken to investigate the effects of intracerebroventricular (i.c.v.) injection of NPS or co-injection of NPSR antagonist on the olfactory behaviors, food intake, and c-Fos expression in olfactory cortex in mice. In addition, dual-immunofluorescence was employed to identify NPS-induced Fos immunereactive (-ir) neurons that also bear NPSR. NPS (0.1–1 nmol) i.c.v. injection significantly reduced the latency to find the buried food, and increased olfactory differentiation of different odors and the total sniffing time spent in olfactory habituation/dishabituation tasks. NPS facilitated olfactory ability most at the dose of 0.5 nmol, which could be blocked by co-injection of 40 nmol NPSR antagonist [D-Val⁵]NPS. NPS administration dose-dependently inhibited food intake in fasted mice. Ex-vivo c-Fos and NPSR immunohistochemistry in the olfactory cortex revealed that, as compared with vehicle-treated mice, NPS markedly enhanced c-Fos expression in the anterior olfactory nucleus (AON), piriform cortex (Pir), ventral tenia tecta (VTT), the anterior cortical amygdaloid nucleus (ACo) and lateral entorhinal cortex (LEnt). The percentage of Fos-ir neurons that also express NPSR were 88.5% and 98.1% in the AON and Pir, respectively. The present findings demonstrated that NPS, via selective activation of the neurons bearing NPSR in the olfactory cortex, facilitates olfactory function in mice.     

tBu-D-Gly5]NPS, a pure and potent antagonist of the neuropeptide S receptor: in vitro and in vivo studies

Neuropeptide S (NPS) regulates various biological functions by selectively activating the NPS receptor (NPSR). Recently, the NPSR ligand [(t)Bu-D-Gly(5)]NPS was generated and in vitro characterized as a pure antagonist at the mouse NPSR. In the present study the pharmacological profile of [(t)Bu-D-Gly(5)]NPS has been investigated. [(t)Bu-D-Gly(5)]NPS activity was evaluated in vitro in the calcium mobilization assay at the rat NPSR and in vivo in the locomotor activity and righting reflex tests in mice and in the elevated plus maze and defensive burying assays in rats. In vitro, [(t)Bu-D-Gly(5)]NPS was inactive per se while it inhibited the calcium mobilization induced by 30 nM NPS (pK(B) 7.42). In Schild analysis experiments [(t)Bu-D-Gly(5)]NPS (0.1-10 μM) produced a concentration-dependent rightward shift of the concentration-response curve to NPS, showing a pA(2) value of 7.17. In mouse locomotor activity experiments, supraspinal injection of [(t)Bu-D-Gly(5)]NPS (1-10 nmol) dose dependently counteracted NPS (0.1 nmol) stimulant effects. In the mouse righting reflex assay [(t)Bu-D-Gly(5)]NPS (0.1-10 nmol) fully prevented the arousal-promoting action of the natural peptide (0.1 nmol). Finally, [(t)Bu-D-Gly(5)]NPS (3-30 nmol) was able to completely block NPS (1 nmol) anxiolytic-like actions in rat elevated plus maze and defensive burying assays. Collectively, the present results demonstrated that [(t)Bu-D-Gly(5)]NPS behaves both in vitro and in vivo as a pure and potent NPSR antagonist. This compound represents a novel and useful tool for investigating the pharmacology and neurobiology of the NPS/NPSR system.     

Synthesis and evaluation of a new series of Neuropeptide S receptor antagonists

Administration of Neuropeptide S (NPS) has been shown to produce arousal, that is, independent of novelty and to induce wakefulness by suppressing all stages of sleep, as demonstrated by EEG recordings in rat. Medicinal chemistry efforts have identified a quinolinone class of potent NPSR antagonists that readily cross the blood–brain barrier. We detail here optimization efforts resulting in the identification of a potent NPSR antagonist which dose-dependently and specifically inhibited ¹²⁵I-NPS binding in the CNS when administered to rats.     

Structure-activity studies on neuropeptide S: identification of the amino acid residues crucial for receptor activation

Neuropeptide S (NPS) has been recently recognized as the endogenous ligand for the previous orphan G-protein-coupled receptor GPR154, now referred to as the NPS receptor (NPSR). The NPS-NPSR receptor system regulates important biological functions such as sleeping/wakening, locomotion, anxiety, and food intake. To collect information on the mechanisms of interaction between NPS and its receptor, a classical structure-activity relationship study was performed. Human (h) NPS derivatives obtained by Ala and d-scan and N- and C-terminal truncation were assessed for their ability to stimulate calcium release in HEK293 cells expressing the human recombinant NPSR. The results of this study indicate that (i) the effect of hNPS is mimicked by the fragment hNPS-(1-10); (ii) Phe(2), Arg(3), and Asn(4) are crucial for biological activity; (iii) the sequence Thr(8)-Gly(9)-Met(10) is important for receptor activation, although with non-stringent chemical requirements; and (iv) the sequence Val(6)-Gly(7) acts as a hinge region between the two above-mentioned domains. However, the stimulatory effect of hNPS given intracerebroventricularly on mouse locomotor activity was not fully mimicked by hNPS-(1-10), suggesting that the C-terminal region of the peptide maintains importance for in vivo activity. In conclusion, this study identified the amino acid residues of this peptide most important for receptor activation.     

Effect of neuropeptide S receptor antagonists and partial agonists on palatable food consumption in the rat

Neuropeptide S (NPS) is the endogenous ligand for the previously orphan G-protein-coupled-receptor, now termed NPS receptor (NPSR). NPS has both anxiolytic and pro-arousal properties and decreases food intake. In this work we use a rat model of palatable food intake to test in vivo different analogs of human NPS developed in our laboratories and characterized in previous in vitro experiments as partial agonists ([Ala³]NPS and [Aib⁵]NPS), or antagonists ([d-Cys(^tBu)⁵]NPS and [^tBu-d-Gly⁵]NPS). Our results confirmed that intracerebroventricular (ICV) injection of NPS (1 nmol) decreases standard chow intake in food restricted rats as well as in freely feeding animals fed with standard or palatable food diets. [Aib⁵]NPS (30 and 60 nmol), like NPS, reduced palatable food intake, thus confirming in vivo its ability to activate NPSR. [Ala³]NPS (60 nmol) did not affect palatable food intake per se but blocked the anorectic effect of NPS, thus suggesting its ability to function as an antagonist in this model. Finally, [d-Cys(^tBu)⁵]NPS (20-60 nmol) and [^tBu-d-Gly⁵]NPS (10-30 nmol), described in previous in vitro studies as pure NPSR antagonists, did not affect palatable food intake when given alone, but fully blocked the anorectic effect of NPS. These results provide an important characterization of the pharmacological properties of these NPS analogs in vivo. Of particular relevance are the data showing that [d-Cys(^tBu)⁵]NPS and [^tBu-d-Gly⁵]NPS behave as pure antagonists at NPSR regulating food intake, indicating that these molecules are suitable tools for further investigation of the physiopharmacology of the NPS/NPSR system.